WO2002080842A3 - Medicament and method for diagnosing an autoimmune condition_in particular psoriasis - Google Patents

Medicament and method for diagnosing an autoimmune condition_in particular psoriasis Download PDF

Info

Publication number
WO2002080842A3
WO2002080842A3 PCT/SE2002/000669 SE0200669W WO02080842A3 WO 2002080842 A3 WO2002080842 A3 WO 2002080842A3 SE 0200669 W SE0200669 W SE 0200669W WO 02080842 A3 WO02080842 A3 WO 02080842A3
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
pat1
medicament
autoimmune disease
diagnosing
Prior art date
Application number
PCT/SE2002/000669
Other languages
French (fr)
Other versions
WO2002080842A2 (en
Inventor
Gunnar Swanbeck
Ian Purvis
Colin Dykes
Duncan Hewett
Original Assignee
Estetecon Ab
Gunnar Swanbeck
Ian Purvis
Colin Dykes
Duncan Hewett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0108587A external-priority patent/GB0108587D0/en
Priority claimed from GB0108589A external-priority patent/GB0108589D0/en
Priority claimed from GB0108590A external-priority patent/GB0108590D0/en
Application filed by Estetecon Ab, Gunnar Swanbeck, Ian Purvis, Colin Dykes, Duncan Hewett filed Critical Estetecon Ab
Priority to AU2002249740A priority Critical patent/AU2002249740A1/en
Publication of WO2002080842A2 publication Critical patent/WO2002080842A2/en
Publication of WO2002080842A3 publication Critical patent/WO2002080842A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)

Abstract

The present invention relates to novel polynucleotides and polypeptides, a therapeutic modulator for use in preventing or treating autoimmune disease and to a method of screening for the modulator, as well as a method to the diagnosis of autoimmune disease, (in particular psoriasis, type I diabetes and rheumatoid arthritis). Linkage disequilibrium mapping is used to localise a psoriasis susceptibility locus and specific polymorphisms in this locus. In particular the invention relates to the use of an agent that modulates PAT1 (Psoriasis Associated Transporter 1) or a , component which: (i)regulates cation-chloride transport,or (ii) is affected by cation-chloride transport, or (iii) regulates PAT1, or (iv) is affected by PAT1; in the manufacture of a medicament for preventing or treating autoimmune disease.
PCT/SE2002/000669 2001-04-05 2002-04-04 Medicament and method for diagnosing an autoimmune condition_in particular psoriasis WO2002080842A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002249740A AU2002249740A1 (en) 2001-04-05 2002-04-04 Medicament and method for diagnosing an autoimmune condition_in particular psoriasis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0108589.3 2001-04-05
GB0108590.1 2001-04-05
GB0108587.7 2001-04-05
GB0108587A GB0108587D0 (en) 2001-04-05 2001-04-05 Diagnosis
GB0108589A GB0108589D0 (en) 2001-04-05 2001-04-05 Therapeutic agent
GB0108590A GB0108590D0 (en) 2001-04-05 2001-04-05 Medicament

Publications (2)

Publication Number Publication Date
WO2002080842A2 WO2002080842A2 (en) 2002-10-17
WO2002080842A3 true WO2002080842A3 (en) 2003-01-23

Family

ID=27256138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2002/000669 WO2002080842A2 (en) 2001-04-05 2002-04-04 Medicament and method for diagnosing an autoimmune condition_in particular psoriasis

Country Status (2)

Country Link
AU (1) AU2002249740A1 (en)
WO (1) WO2002080842A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248248A1 (en) * 2001-03-30 2004-12-09 Marion Webster Isolated human transporters proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
CA2519241A1 (en) * 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2212701A4 (en) * 2007-11-28 2011-10-05 Redoxis Ab New treatment of autoimmune conditions
CA3148095A1 (en) * 2019-07-24 2021-01-28 Agenus Inc. Antigenic polypeptides and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029431A1 (en) * 1996-12-31 1998-07-09 Yale University Method to diagnose and treat pathological conditions resulting from deficient ion transport

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029431A1 (en) * 1996-12-31 1998-07-09 Yale University Method to diagnose and treat pathological conditions resulting from deficient ion transport

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ENLUND FREDRIK ET AL.: "Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from Southwest Sweden", EUROPEAN JOURNAL OF HUMAN GENETICS, vol. 7, 1999, pages 783 - 790, XP002956240 *
HEWETT DUNCAN ET AL.: "Identification of a sporiasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map", GENOMICS, vol. 79, no. 3, March 2002 (2002-03-01), pages 305 - 314, XP002956242 *
LEE YOUNG-AE ET AL.: "A major susceptilibity locus for atopic dermatitis maps to chromosome 3q21", NATURE GENETICS, vol. 26, December 2000 (2000-12-01), pages 470 - 473, XP002956243 *
PANET RIVKA ET AL.: "Overexpression of the Na+/K+/C1-cotransporter gene induces cell proliferation and phenotypic transformation in mouse fibroblasts", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 182, 2000, pages 109 - 118, XP008010154 *
SEMPLICINI A. ET AL.: "Red blood cell sodium and potassium fluxes in psoriatic patients", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 18, 1988, pages 47 - 51, XP002956241 *

Also Published As

Publication number Publication date
AU2002249740A1 (en) 2002-10-21
WO2002080842A2 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
CA2204616A1 (en) Ppar gamma antagonists for treating obesity
WO2002096415A3 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
DE69400493D1 (en) Use of rifaximin and rifaximin-containing pharmaceutical compositions for the treatment of gastric dyspepsia caused by Helicobacter pylori
ATE196651T1 (en) DNA CODING FOR THE ALPHA-1E SUBUNIT OF THE HUMAN CALCIUM CHANNEL
WO2002080842A3 (en) Medicament and method for diagnosing an autoimmune condition_in particular psoriasis
HK1041714A1 (en) A-beta-peptide screening assay
ZA988095B (en) New peptide mimetics for the treatment of bone metabolic disorders, methods for their production, and drugs containing these compounds.
WO2003048323A3 (en) Polynucleotides and polypeptides associated with the development of rheumatoid arthritis
WO2004026258A3 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease
WO2001008635A3 (en) Calcium channel transport polynucleotides, polypeptides, and antibodies
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
WO2001019851A3 (en) Opaminergic neuronal survival-promoting factors and uses thereof
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
PL353065A1 (en) Novel polypeptide and dna thereof
WO2003102161A3 (en) Methods of diagnosing & treating diabetes and insulin resistance
WO2003103601A3 (en) Methods of diagnosing & treating diabetes and insulin resistance
WO2002060934A3 (en) IDENTIFICATION OF THE ANTI-σ28 FACTOR IN HELICOBACTER PYLORI, IN CAMPYLOBACTER JEJUNI AND IN PSEUDOMONAS AERUGINOSA AND APPLICATION THEREOF
AU2003235113A1 (en) Method of measuring neprilysin activity
EP0913472A3 (en) Human LIG-1 Homolog (HLIG-1)
WO2002097079A3 (en) Gene encoding molecular motor protein and diagnosis method for the disease related to the gene
WO2002068687A8 (en) Function and application of tob gene in central nervous system of mammal
WO2001064875A3 (en) Human transporter genes and proteins encoded thereby
WO2000042165A3 (en) Bone marrow-specific protein
GB2361061A (en) Single necleotide polymorphism in a pyruvate dehydrogenase kinase isoenzyme 2 (PDK2) in humans
ES2150585T3 (en) PROCEDURE FOR THE DIAGNOSTIC EVALUATION AND CONTROL OF THE EVOLUTION OF STATES OF SHOCK IN HUMAN BEINGS, AS WELL AS MEDICINES FOR ITS THERAPY.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP